vs

Side-by-side financial comparison of B&G Foods, Inc. (BGS) and LivaNova PLC (LIVN). Click either name above to swap in a different company.

B&G Foods, Inc. is the larger business by last-quarter revenue ($439.3M vs $360.9M, roughly 1.2× LivaNova PLC). LivaNova PLC runs the higher net margin — 8.6% vs -4.4%, a 12.9% gap on every dollar of revenue. On growth, LivaNova PLC posted the faster year-over-year revenue change (12.1% vs -4.7%). LivaNova PLC produced more free cash flow last quarter ($50.2M vs $-70.7M). Over the past eight quarters, LivaNova PLC's revenue compounded faster (10.6% CAGR vs -12.8%).

B&G Foods, Inc. is an American branded foods holding company based in Parsippany, New Jersey. The company was formed in 1996 to acquire Bloch & Guggenheimer, a Manhattan-based producer of pickles, relish and condiments which had been founded in 1889.

LivaNova, plc is an American medical device manufacturer based in the UK. The company develops devices used for cardiac surgery and neuromodulation. The company was formed in 2015 by a $2.7B merger between Houston, Texas-based Cyberonics, Inc. and Milan, Italy-based Sorin S.p.a. The company trades on the NASDAQ stock exchange under the ticker symbol "LIVN".

BGS vs LIVN — Head-to-Head

Bigger by revenue
BGS
BGS
1.2× larger
BGS
$439.3M
$360.9M
LIVN
Growing faster (revenue YoY)
LIVN
LIVN
+16.9% gap
LIVN
12.1%
-4.7%
BGS
Higher net margin
LIVN
LIVN
12.9% more per $
LIVN
8.6%
-4.4%
BGS
More free cash flow
LIVN
LIVN
$120.9M more FCF
LIVN
$50.2M
$-70.7M
BGS
Faster 2-yr revenue CAGR
LIVN
LIVN
Annualised
LIVN
10.6%
-12.8%
BGS

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
BGS
BGS
LIVN
LIVN
Revenue
$439.3M
$360.9M
Net Profit
$-19.1M
$30.9M
Gross Margin
22.5%
65.2%
Operating Margin
2.5%
11.8%
Net Margin
-4.4%
8.6%
Revenue YoY
-4.7%
12.1%
Net Profit YoY
-356.5%
-44.7%
EPS (diluted)
$-0.24
$0.57

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BGS
BGS
LIVN
LIVN
Q4 25
$360.9M
Q3 25
$439.3M
$357.8M
Q2 25
$424.4M
$352.5M
Q1 25
$425.4M
$316.9M
Q4 24
$551.6M
$321.8M
Q3 24
$461.1M
$318.1M
Q2 24
$444.6M
$318.6M
Q1 24
$475.2M
$294.9M
Net Profit
BGS
BGS
LIVN
LIVN
Q4 25
$30.9M
Q3 25
$-19.1M
$26.8M
Q2 25
$-9.8M
$27.2M
Q1 25
$835.0K
$-327.3M
Q4 24
$-222.4M
$55.9M
Q3 24
$7.5M
$33.0M
Q2 24
$3.9M
$16.3M
Q1 24
$-40.2M
$-41.9M
Gross Margin
BGS
BGS
LIVN
LIVN
Q4 25
65.2%
Q3 25
22.5%
68.4%
Q2 25
20.5%
67.8%
Q1 25
21.2%
69.7%
Q4 24
21.5%
68.2%
Q3 24
22.2%
70.8%
Q2 24
20.7%
68.7%
Q1 24
22.9%
70.3%
Operating Margin
BGS
BGS
LIVN
LIVN
Q4 25
11.8%
Q3 25
2.5%
15.1%
Q2 25
5.2%
15.4%
Q1 25
8.4%
15.3%
Q4 24
-46.6%
11.5%
Q3 24
11.1%
11.2%
Q2 24
9.9%
12.6%
Q1 24
-3.3%
5.5%
Net Margin
BGS
BGS
LIVN
LIVN
Q4 25
8.6%
Q3 25
-4.4%
7.5%
Q2 25
-2.3%
7.7%
Q1 25
0.2%
-103.3%
Q4 24
-40.3%
17.4%
Q3 24
1.6%
10.4%
Q2 24
0.9%
5.1%
Q1 24
-8.5%
-14.2%
EPS (diluted)
BGS
BGS
LIVN
LIVN
Q4 25
$0.57
Q3 25
$-0.24
$0.49
Q2 25
$-0.12
$0.50
Q1 25
$0.01
$-6.01
Q4 24
$-2.81
$1.04
Q3 24
$0.09
$0.60
Q2 24
$0.05
$0.30
Q1 24
$-0.51
$-0.78

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BGS
BGS
LIVN
LIVN
Cash + ST InvestmentsLiquidity on hand
$60.9M
$635.6M
Total DebtLower is stronger
$2.0B
$376.1M
Stockholders' EquityBook value
$470.7M
$1.2B
Total Assets
$2.9B
$2.6B
Debt / EquityLower = less leverage
4.30×
0.31×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BGS
BGS
LIVN
LIVN
Q4 25
$635.6M
Q3 25
$60.9M
$646.1M
Q2 25
$54.1M
$593.6M
Q1 25
$61.2M
$738.4M
Q4 24
$50.6M
$428.9M
Q3 24
$54.7M
$346.4M
Q2 24
$40.3M
$329.2M
Q1 24
$42.5M
$309.2M
Total Debt
BGS
BGS
LIVN
LIVN
Q4 25
$376.1M
Q3 25
$2.0B
$434.5M
Q2 25
$2.0B
$430.6M
Q1 25
$2.0B
$628.2M
Q4 24
$2.0B
$627.0M
Q3 24
$2.1B
$625.5M
Q2 24
$2.0B
$624.5M
Q1 24
$2.0B
$623.8M
Stockholders' Equity
BGS
BGS
LIVN
LIVN
Q4 25
$1.2B
Q3 25
$470.7M
$1.2B
Q2 25
$501.4M
$1.1B
Q1 25
$513.1M
$1.0B
Q4 24
$524.8M
$1.3B
Q3 24
$755.3M
$1.3B
Q2 24
$765.0M
$1.2B
Q1 24
$781.2M
$1.2B
Total Assets
BGS
BGS
LIVN
LIVN
Q4 25
$2.6B
Q3 25
$2.9B
$2.6B
Q2 25
$2.9B
$2.5B
Q1 25
$3.0B
$2.6B
Q4 24
$3.0B
$2.5B
Q3 24
$3.4B
$2.5B
Q2 24
$3.4B
$2.5B
Q1 24
$3.4B
$2.5B
Debt / Equity
BGS
BGS
LIVN
LIVN
Q4 25
0.31×
Q3 25
4.30×
0.38×
Q2 25
3.97×
0.38×
Q1 25
3.91×
0.61×
Q4 24
3.85×
0.47×
Q3 24
2.75×
0.48×
Q2 24
2.67×
0.50×
Q1 24
2.61×
0.51×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BGS
BGS
LIVN
LIVN
Operating Cash FlowLast quarter
$-64.6M
$82.4M
Free Cash FlowOCF − Capex
$-70.7M
$50.2M
FCF MarginFCF / Revenue
-16.1%
13.9%
Capex IntensityCapex / Revenue
1.4%
8.9%
Cash ConversionOCF / Net Profit
2.67×
TTM Free Cash FlowTrailing 4 quarters
$54.8M
$173.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BGS
BGS
LIVN
LIVN
Q4 25
$82.4M
Q3 25
$-64.6M
$85.1M
Q2 25
$17.8M
$62.9M
Q1 25
$52.7M
$24.0M
Q4 24
$80.3M
$78.7M
Q3 24
$4.2M
$51.0M
Q2 24
$11.3M
$43.4M
Q1 24
$35.1M
$10.0M
Free Cash Flow
BGS
BGS
LIVN
LIVN
Q4 25
$50.2M
Q3 25
$-70.7M
$62.2M
Q2 25
$11.5M
$47.8M
Q1 25
$42.4M
$13.2M
Q4 24
$71.7M
$68.3M
Q3 24
$-679.0K
$32.8M
Q2 24
$5.2M
$31.2M
Q1 24
$27.5M
$3.6M
FCF Margin
BGS
BGS
LIVN
LIVN
Q4 25
13.9%
Q3 25
-16.1%
17.4%
Q2 25
2.7%
13.6%
Q1 25
10.0%
4.2%
Q4 24
13.0%
21.2%
Q3 24
-0.1%
10.3%
Q2 24
1.2%
9.8%
Q1 24
5.8%
1.2%
Capex Intensity
BGS
BGS
LIVN
LIVN
Q4 25
8.9%
Q3 25
1.4%
6.4%
Q2 25
1.5%
4.3%
Q1 25
2.4%
3.4%
Q4 24
1.6%
3.2%
Q3 24
1.0%
5.7%
Q2 24
1.4%
3.8%
Q1 24
1.6%
2.2%
Cash Conversion
BGS
BGS
LIVN
LIVN
Q4 25
2.67×
Q3 25
3.18×
Q2 25
2.32×
Q1 25
63.17×
Q4 24
1.41×
Q3 24
0.56×
1.55×
Q2 24
2.87×
2.65×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BGS
BGS

Specialty Segment$150.5M34%
Meals Segment$110.0M25%
Spices And Flavor Solutions Segment$101.4M23%
Frozen And Vegetables Segment$77.4M18%

LIVN
LIVN

Other$169.4M47%
Neuromodulation Segment$119.7M33%
Cardiopulmonary Segment$71.8M20%

Related Comparisons